Medicenna Therapeutics Corp logo

Medicenna Therapeutics Corp

TSX:MDNA (Canada)  
C$ 2.49 (+27.69%) Apr 26
At Loss
P/B:
6.12
Market Cap:
C$ 173.40M ($ 126.75M)
Enterprise V:
C$ 151.64M ($ 110.84M)
Volume:
736.98K
Avg Vol (2M):
166.63K
Also Trade In:
Volume:
736.98K
At Loss
Avg Vol (2M):
166.63K

Business Description

Description
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.8
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 86.34
9-Day RSI 76.72
14-Day RSI 71.8
6-1 Month Momentum % 362.69
12-1 Month Momentum % 63.16

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.77
Quick Ratio 5.77
Cash Ratio 5.4

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -14.2
Name Current Vs Industry Vs History
ROE % -58.54
ROA % -49.05
ROIC % -29406.67
ROCE % -63.27

Financials (Next Earnings Date:2024-06-27 Est.)

TSX:MDNA's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Medicenna Therapeutics Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil C$)
EPS (TTM) (C$) -0.22
Beta 2.84
Volatility % 206.48
14-Day RSI 71.8
14-Day ATR (C$) 0.226109
20-Day SMA (C$) 1.814
12-1 Month Momentum % 63.16
52-Week Range (C$) 0.215 - 2.62
Shares Outstanding (Mil) 69.64

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Medicenna Therapeutics Corp Filings

Filing Date Document Date Form
No Filing Data

Medicenna Therapeutics Corp Stock Events

Financials Calendars
Event Date Price(C$)
No Event Data

Medicenna Therapeutics Corp Frequently Asked Questions

What is Medicenna Therapeutics Corp(TSX:MDNA)'s stock price today?
The current price of TSX:MDNA is C$2.49. The 52 week high of TSX:MDNA is C$2.62 and 52 week low is C$0.22.
When is next earnings date of Medicenna Therapeutics Corp(TSX:MDNA)?
The next earnings date of Medicenna Therapeutics Corp(TSX:MDNA) is 2024-06-27 Est..
Does Medicenna Therapeutics Corp(TSX:MDNA) pay dividends? If so, how much?
Medicenna Therapeutics Corp(TSX:MDNA) does not pay dividend.

Press Release

Subject Date
No Press Release